DECADRON W/ XYLOCAINE
LOE Approachingdexamethasone sodium phosphate; lidocaine hydrochloride
NDAINJECTIONINJECTABLE
Approved
Jul 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DECADRON W/ XYLOCAINE (dexamethasone sodium phosphate; lidocaine hydrochloride) by Merck & Co.. Approved for rheumatoid arthritis, rheumatoid arthritis, psoriasis and 10 more indications. First approved in 1962.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECADRON W/ XYLOCAINE is a fixed combination injectable containing dexamethasone sodium phosphate (corticosteroid) and lidocaine hydrochloride (local anesthetic), approved in 1962. It treats inflammatory and autoimmune conditions including rheumatoid arthritis, asthma, ulcerative colitis, multiple sclerosis, and hematologic malignancies via anti-inflammatory and immunosuppressive mechanisms. The lidocaine component provides local anesthetic benefit at the injection site.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); legacy brand likely operating with maintenance-focused, smaller commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (11)
Worked on DECADRON W/ XYLOCAINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.